<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862992</url>
  </required_header>
  <id_info>
    <org_study_id>A002-A3</org_study_id>
    <nct_id>NCT00862992</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia</brief_title>
  <official_title>Phase II Study of MP-214 in Patients With Schizophrenia (Exploratory Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed
      doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets
      will be administered to patients starting at an initial dose, followed by up-titration to a
      fixed dose (low, medium or high) for 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse event, Adverse drug Reaction</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: PANSS total score, CGI-S and CGI-I</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine low dose</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Cariprazine(INN)</other_name>
    <other_name>RGH-188</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine medium dose</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine high dose</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting DSM-IV-TR criteria for schizophrenia

          -  PANSS total score &lt;= 120 during the observation period

          -  Patients who have been treated with oral antipsychotics within 4 weeks before informed
             consent

          -  Patients whose consent is obtained from themselves in written form

        Exclusion Criteria:

          -  Patients who have defined as any mental disorder other than &quot;Schizophrenia&quot; based on
             the criteria of DSM-IV-TR

          -  History of drug or alcohol abuse

          -  Concurrent Parkinson's disease

          -  History of, or concurrent spastic disorders like epilepsy, cerebrovascular disease,
             anuresis or adynamic(= paralytic) ileus, malignant syndrome, diabetes, hepatic
             disorder

          -  Patients who exhibit abnormalities on Physical Examination, have abnormal vital signs,
             ECG, or clinical laboratory values

          -  Current cataract during the observation period

          -  History of shock or anaphylactoid symptoms to drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teruhiko Higuchi, President</last_name>
    <role>Study Chair</role>
    <affiliation>National Center of Neurology and Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoyu Hospital</name>
      <address>
        <city>Kure-City</city>
        <state>Hiroshima-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2009</study_first_submitted>
  <study_first_submitted_qc>March 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>General Manager, Clinical Research Department I</name_title>
    <organization>Mitsubishi Tanabe Pharma Corporation</organization>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>dopamine D3/D2 antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

